Quick Answer
PharmaCyte Biotech, Inc. reported Research And Development Expense of $438.4 thousand for the year ending 2025.
- PharmaCyte Biotech, Inc. showed an increase of +7.6% in Research And Development Expense from 2024 to 2025.
- This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $0.00 | Q1 2014: $0.00 | Q3 2014: $0.00 | Q4 2014: $347.8 thousand | Q1 2015: $273.8 thousand | Q3 2015: $155.7 thousand | Q4 2015: $439.7 thousand | Q1 2016: $574.0 thousand | Q3 2016: $175.0 thousand | Q4 2016: $253.8 thousand | Q1 2017: $579.7 thousand | Q3 2017: $427.7 thousand | Q4 2017: $515.5 thousand | Q1 2018: $802.6 thousand | Q3 2018: $267.8 thousand | Q4 2018: $115.1 thousand | Q1 2019: $59.1 thousand | Q3 2019: $72.3 thousand | Q4 2019: $17.9 thousand | Q1 2020: $113.3 thousand | Q3 2020: $270.6 thousand | Q4 2020: $151.3 thousand | Q1 2021: $174.1 thousand | Q3 2021: $143.6 thousand | Q4 2021: $135.2 thousand | Q1 2022: $158.0 thousand | Q3 2022: $159.3 thousand | Q4 2022: $178.0 thousand | Q1 2023: $45.4 thousand | Q3 2023: $104.5 thousand | Q4 2023: $82.0 thousand | Q1 2024: $126.7 thousand | Q3 2024: $96.0 thousand | Q4 2024: $97.5 thousand | Q1 2025: $118.2 thousand | Q3 2025: $95.2 thousand | Q4 2025: $141.1 thousand | Q1 2026: $93.1 thousand.
- Historical annual values: Fiscal year 2025: $438.4 thousand | Fiscal year 2024: $407.4 thousand | Fiscal year 2023: $468.5 thousand | Fiscal year 2022: $690.9 thousand | Fiscal year 2021: $916.2 thousand | Fiscal year 2020: $301.2 thousand | Fiscal year 2019: $460.1 thousand | Fiscal year 2018: $2.00 million | Fiscal year 2017: $1.18 million | Fiscal year 2016: $1.41 million | Fiscal year 2015: $3.48 million | Fiscal year 2014: $323.5 thousand | Fiscal year 2013: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: